AVEO Pharmaceuticals Culture Company

Dr. Michael N. Needle, also known as Mike, M.D., has been the Chief Medical Officer of AVEO Pharmaceuticals, Inc. since January 9, 2015. Dr. Needle served as the Chief Medical Officer and Chief Medical Officer of Multiple Myeloma Research Consortium and The Multiple Myeloma Research Foundation, Inc. since April 9, 2012. He served as Vice President of Clinical Affairs at Imclone Systems Inc. since January 2001. He served as the Chief Medical Officer of Array BioPharma, Inc., from April 2013 to September 2014. He has more than 15 years of pharmaceutical industry experience in drug development and regulatory affairs. Dr. Needle has built an extensive network of key opinion leaders, business leaders at top biotechnology and pharmaceutical companies, medical leaders at academic centers and the FDA. He has deep industry experience includes prominent roles on the development of important oncology and hematology drugs including Erbitux(R) (cetuximab), Revlimid(R) (lenalidomide) and Pomalyst(R) (pomolidimide). At MMRF, he served Vice President level positions at Celgene in Clinical Research and Development in Oncology, Strategic Medical Business Development and Pediatric Strategy. He also served as Vice President of Clinical Affairs at ImClone Systems Incorporated. He served faculty positions at the University of Pennsylvania and Columbia University. He has fellowship in Pediatric Hematology / Oncology at the Children's Hospital Medical Center and the Fred Hutchinson Cancer Research Center of the University of Washington in Seattle and the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Needle graduated from Binghamton University with a Bachelor of Arts in Physics and Medical Degree from SUNY Downstate Medical Center, in Brooklyn, New York.

Mr. Matthew D. Dallas, also known as Matt, has been the Chief Financial Officer and Treasurer of CoLucid Pharmaceuticals, Inc. since February 9, 2015. Mr. Dallas has been the Chief Financial Officer of AVEO Pharmaceuticals, Inc. since June 1, 2017. He has 18 years of finance experience including 16 years in the biotechnology and life sciences industry. He served as Vice President of Finance and Treasurer at AVEO Pharmaceuticals, Inc. from July 2014 to February 2015 and served as its Principal Accounting Officer. Mr. Dallas served as Acting Principal Accounting Officer, Senior Director of Finance and Director of Financial Planning & Analysis at AVEO Pharmaceuticals, Inc. from July 2012 to June 2013 and also served as its Associate Director of Financial Planning and Analysis from March 2011 to June 2012. He has responsibility for the AVEO's Finance, IT and Facilities functions. He previously served as AVEO's Senior Director of Finance and Director of Financial Planning and Analysis. Prior to joining AVEO in 2011, he worked at Genzyme Corporation from December 2000 to March 2011, NEN Life Sciences and Kimberly-Clark Corporation where he held various positions in finance and accounting. He served as the Vice President of Finance and Treasurer at AVEO Oncology with responsibility for AVEO's Finance, Information Technology and Facilities functions. Mr. Dallas holds a B.S. in Finance from the University of Tennessee in Knoxville.